Short answer
Corvus Pharmaceuticals, Inc. (CRVS) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2026 results and March 31, 2026 financial position disclosed through furnished Exhibit 99.1.
Corvus Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results and March 31, 2026 financial position disclosed through furnished Exhibit 99.1
- Business update included alongside quarterly financial results
- Investors should review Exhibit 99.1 for operating metrics, cash position, and management commentary
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Corvus Pharmaceuticals, Inc. 8-K filings
Get the next CRVS 8-K as it lands
Follow CRVS for push alerts, or ask the research agent what this filing means.